Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 136 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) Overview 10
Therapeutics Development 11
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Stage of Development 11
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Therapy Area 12
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Indication 13
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Companies 17
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Universities/Institutes 26
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Therapeutics Assessment 28
Assessment by Monotherapy/Combination Products 28
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 35
Advenchen Laboratories, LLC 35
Amgen Inc. 36
ArQule, Inc. 37
Astellas Pharma Inc. 38
AstraZeneca Plc 39
AVEO Pharmaceuticals, Inc. 40
Batu Biologics, Inc. 41
Bayer AG 42
Boehringer Ingelheim GmbH 43
Bristol-Myers Squibb Company 44
Celon Pharma Sp. z o.o. 45
Daiichi Sankyo Company, Limited 46
Debiopharm International SA 47
Eddingpharm 48
Eisai Co., Ltd. 49
Eli Lilly and Company 51
Hutchison MediPharma Limited 52
Incyte Corporation 53
Johnson & Johnson 54
Kaken Pharmaceutical Co., Ltd. 55
Les Laboratoires Servier SAS 56
Nobelpharma Co., Ltd. 57
Novartis AG 58
Principia Biopharma Inc. 59
Vichem Chemie Research Ltd. 60
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drug Profiles 61
ARQ-087 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ASP-5878 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
AZD-4547 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
BAY-1163877 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
BAY-1179470 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
BAY-1187982 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
BMS-986036 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
CPL-043 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Debio-1347 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
DS-1123 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
E-7090 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
EDP-317 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
erdafitinib - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
GP-369 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
HMPL-453 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
INCB-54828 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
infigratinib - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
L-27 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
lenvatinib mesylate - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
lucitanib - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
LY-2874455 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
nintedanib - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
palifermin (recombinant) - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
PRN-1371 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
RPT-835 - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
S-49076 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
trafermin - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
trafermin - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
Vallovax - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Dormant Projects 117
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Discontinued Products 119
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Featured News & Press Releases 122
Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting 122
May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology 122
May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma 123
May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis 124
May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim's new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma 125
Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus 126
Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor 127
Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer 128
Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer 129
Mar 03, 2016: Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm 130
Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug 130
Feb 25, 2016: New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations 131
Jan 27, 2016: NICE recommends nintedanib for idiopathic pulmonary fibrosis 132
Jan 26, 2016: Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease 132
Jan 18, 2016: U.S. FDA Accepts For Priority Review sNDA For Eisai'S Anticancer Agent Lenvatinib Seeking Approval For Renal Cell Carcinoma 133
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 135
Disclaimer 136

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Development by Companies, H1 2016 (Contd..2) 21
Products under Development by Companies, H1 2016 (Contd..3) 22
Products under Development by Companies, H1 2016 (Contd..4) 23
Products under Development by Companies, H1 2016 (Contd..5) 24
Products under Development by Companies, H1 2016 (Contd..6) 25
Number of Products under Investigation by Universities/Institutes, H1 2016 26
Products under Investigation by Universities/Institutes, H1 2016 27
Assessment by Monotherapy/Combination Products, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Pipeline by Advenchen Laboratories, LLC, H1 2016 35
Pipeline by Amgen Inc., H1 2016 36
Pipeline by ArQule, Inc., H1 2016 37
Pipeline by Astellas Pharma Inc., H1 2016 38
Pipeline by AstraZeneca Plc, H1 2016 39
Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 40
Pipeline by Batu Biologics, Inc., H1 2016 41
Pipeline by Bayer AG, H1 2016 42
Pipeline by Boehringer Ingelheim GmbH, H1 2016 43
Pipeline by Bristol-Myers Squibb Company, H1 2016 44
Pipeline by Celon Pharma Sp. z o.o., H1 2016 45
Pipeline by Daiichi Sankyo Company, Limited, H1 2016 46
Pipeline by Debiopharm International SA, H1 2016 47
Pipeline by Eddingpharm, H1 2016 48
Pipeline by Eisai Co., Ltd., H1 2016 49
Pipeline by Eli Lilly and Company, H1 2016 51
Pipeline by Hutchison MediPharma Limited, H1 2016 52
Pipeline by Incyte Corporation, H1 2016 53
Pipeline by Johnson & Johnson, H1 2016 54
Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 55
Pipeline by Les Laboratoires Servier SAS, H1 2016 56
Pipeline by Nobelpharma Co., Ltd., H1 2016 57
Pipeline by Novartis AG, H1 2016 58
Pipeline by Principia Biopharma Inc., H1 2016 59
Pipeline by Vichem Chemie Research Ltd., H1 2016 60
Dormant Projects, H1 2016 117
Dormant Projects (Contd..1), H1 2016 118
Discontinued Products, H1 2016 119
Discontinued Products (Contd..1), H1 2016 120
Discontinued Products (Contd..2), H1 2016 121